MAPT and Alzheimer disease: More recently, clinical diagnosis of AD and AD-related dementia (ADRD) is supported by imaging biomarkers such as positron emission tomography which is relatively expensive for patients, or by CSF biomarkers such as Aβ42, Aβ42/40 ratio, phosphorylated tau, and total tau which involves an invasive spinal tap procedure.